XW043L7Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW043L7
CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.FacebookXLinkedInPrint

XW043L7 is a billable ICD-10-PCS procedure code for Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 018. The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
XW043L7
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
Short Description
Introduce Lifileucel in Central Vein, Perc, New Tech 7
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyLLifileucel Immunotherapy
7Qualifier7New Technology Group 7

Clinical Classification (CCSR)

AHRQ groups XW043L7 into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E043GC — Introduce Oth Therap Subst in Central Vein, Perc

Similar Procedure Codes

Questions About XW043L7

Is XW043L7 a billable code?

Yes. XW043L7 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW043L7 mean?

XW043L7 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character L is the Device/Substance/Technology (Lifileucel Immunotherapy); the 7th character 7 is the Qualifier (New Technology Group 7).

What MS-DRG does XW043L7 group to?

On an inpatient stay, Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7 maps to MS-DRG 018 (chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies). The MS-DRG sets the fixed Medicare payment for the stay.